Debt-to-equity of Allogene Therapeutics, Inc. from 30 Jun 2019 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Allogene Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2019 to 30 Sep 2025.
  • Allogene Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 34%, a 30% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Allogene Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 34% +7.8% +30% 30 Sep 2025
Q2 2025 31% +5.8% +23% 30 Jun 2025
Q1 2025 28% +3.5% +14% 31 Mar 2025
Q4 2024 27% +2.5% +9.9% 31 Dec 2024
Q3 2024 26% +2% +8.2% 30 Sep 2024
Q2 2024 25% +1.7% +7.2% 30 Jun 2024
Q1 2024 25% +3% +14% 31 Mar 2024
Q4 2023 25% +6.4% +35% 31 Dec 2023
Q3 2023 24% +8.1% +50% 30 Sep 2023
Q2 2023 23% +9.5% +68% 30 Jun 2023
Q1 2023 22% +9.9% +83% 31 Mar 2023
Q4 2022 18% +7.2% +64% 31 Dec 2022
Q3 2022 16% +4.6% +40% 30 Sep 2022
Q2 2022 14% +3% +27% 30 Jun 2022
Q1 2022 12% +1.4% +14% 31 Mar 2022
Q4 2021 11% +0.21% +1.9% 31 Dec 2021
Q3 2021 12% +1% +9.6% 30 Sep 2021
Q2 2021 11% -0.34% -3% 30 Jun 2021
Q1 2021 10% -2.5% -19% 31 Mar 2021
Q4 2020 11% -1% -8.6% 31 Dec 2020
Q3 2020 11% -0.51% -4.6% 30 Sep 2020
Q2 2020 11% -11% -48% 30 Jun 2020
Q1 2020 13% 31 Mar 2020
Q4 2019 12% 31 Dec 2019
Q3 2019 11% 30 Sep 2019
Q2 2019 22% 30 Jun 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.